TrialInflammatory bowel diseases2025

Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA®), for the Prevention of Recurrent Clostridioides difficile Infection in Participants With Inflammatory Bowel Disease in PUNCH CD3-OLS.

Jessica R Allegretti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.